tirzepatide nih PDB-101: Diabetes Mellitus: Diabetes Mellitus: undefined: Tirzepatide 10mg Research Peptide (GLP-TZ

Patient Responsibilities Your consent form may outline patient responsibilities, such as: Following prescribed dosing schedules Reporting adverse effects promptly Attending follow-up appointments and ongoing monitoring Alternatives to Treatment Patients should be made aware that they have the right to decline or discontinue treatment and should understand what alternative options may exist

Cagrilintide alone: -11.5% REDEFINE 2 (obesity + T2D): Phase 3, 68 weeks, ~1,200 patients

Both semaglutide and metformin can trigger gastrointestinal issues, but the intensity and frequency of these side effects vary between the two

PMC 12629041

Cai W, Tucholski TM, Gregorich ZR, Ge Y